(Q37903747)

25 August 2017

1 reference

title

Biomarkers: optimizing treatment guidance in heart failure (English)

1 reference

25 August 2017

0 references

0 references

7

Faiez Zannad

1 reference

25 August 2017

2

Adriaan A Voors

1 reference

25 August 2017

Michael Böhm

1

1 reference

25 August 2017

Jean-Marie Ketelslegers

3

1 reference

25 August 2017

Stephan H Schirmer

4

1 reference

25 August 2017

Eva Turgonyi

5

1 reference

25 August 2017

Peter Bramlage

6

1 reference

25 August 2017

publication date

16 July 2011

1 reference

Clinical Research in Cardiology

25 August 2017

published in

1 reference

25 August 2017

volume

100

1 reference

25 August 2017

issue

11

1 reference

25 August 2017

page(s)

973-981

1 reference

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Clinical epidemiology of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Cancer survival in European adolescents and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Trends in prevalence and outcome of heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Novel markers for heart failure diagnosis and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure : a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Biomarkers in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Cardiac remodeling and failure: from molecules to man (Part I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocard

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Atrial natriuretic peptide, B-type natriuretic peptide, and serum collagen markers after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Rapid cardiovascular action of aldosterone in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Eplerenone in patients with systolic heart failure and mild symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Differential associations between renal function and "modifiable" risk factors in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Elevated blood urea nitrogen-to-creatinine ratio increased the risk of hospitalization and all-cause death in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Structure and expression of the human cystatin C gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Molecular cloning and sequence analysis of cDNA coding for the precursor of the human cysteine proteinase inhibitor cystatin C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Cystatin C in acute heart failure without advanced renal impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Albuminuria in chronic heart failure: prevalence and prognostic importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

High prevalence of microalbuminuria in chronic heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Low-grade albuminuria and cardiovascular risk : what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Risk stratification of chronic heart failure patients by multiple biomarkers: implications of BNP, H-FABP, and PTX3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Multimarker approach for the prediction of heart failure incidence in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Cardiac troponin-I and risk of heart failure: a community-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Novel metabolic risk factors for heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Use of multiple biomarkers to improve the prediction of death from cardiovascular causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Myocardial collagen metabolism in failing hearts before and during cardiac resynchronization therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Frequency of albuminuria in primary care: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-011-0341-0

Monitoring tissue repair and fibrosis from a distance

21 January 2018

1 reference

12 December 2020

Adiponectin and risk of congestive heart failure

1 reference

12 December 2020

Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor

1 reference

12 December 2020

Changes of collagen metabolism predict the left ventricular remodeling after myocardial infarction

1 reference

12 December 2020

Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure

1 reference

12 December 2020

Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction

1 reference

12 December 2020

Serum Carboxy-Terminal Propeptide of Procollagen Type I Is a Marker of Myocardial Fibrosis in Hypertensive Heart Disease

1 reference

12 December 2020

Long-term changes in collagen formation expressed by serum carboxyterminal propeptide of type-I procollagen and relation to left ventricular function after acute myocardial infarction

1 reference

12 December 2020

Circulating levels of carboxyterminal propeptide of type I procollagen and left ventricular remodeling after myocardial infarction

1 reference

12 December 2020

Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass

1 reference

12 December 2020

High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction

1 reference

12 December 2020

Serum aminoterminal type III procollagen peptide reflects repair after acute myocardial infarction

1 reference

12 December 2020

Benchmarks for the assessment of novel cardiovascular biomarkers

1 reference

12 December 2020

The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction

1 reference

12 December 2020

Aldosterone: a mediator of myocardial necrosis and renal arteriopathy

1 reference

12 December 2020

Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities

1 reference

12 December 2020

Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations

1 reference

12 December 2020

Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects

1 reference

12 December 2020

10.1007/S00392-011-0341-0

Identifiers

DOI

1 reference

25 August 2017

1 reference